Browse News
Filter News
Found 5 articles
-
Ubix Therapeutics has announced a collaboration agreement with SK Biopharmaceuticals, and Engitix and Takeda are teaming up to develop a therapeutic for fibrostenotic IBD.
-
UBIX THERAPEUTICS, SK BIOPHARMACEUTICALS ENTER INTO RESEARCH COLLABORATION AGREEMENT TO DEVELOP NOVEL THERAPEUTICS BASED ON TARGETED PROTEIN DEGRADATION
4/14/2022
Ubix Therapeutics, SK Biopharmaceuticals to develop new compounds and medicines through Ubix’s Degraducer® technology for cancer treatment.
-
UBIX THERAPEUTICS KICK OFF AN IND-ENABLING STUDIS OF BRUTON’S TYROSINE KINASE DEGRADER
7/20/2021
South Korea-based biotech company, Ubix Therapeutics (en.ubixtrx.com), announced the current status of their lead program, UBX-303, which utilizes Ubix’s platform technology, Degraducer®.
-
Debiopharm and Ubix Therapeutics Launch Research to Develop a New Anti-Cancer Modality - Antibody Degraducer® Conjugates
6/16/2021
Debiopharm today announced their co-research agreement combining two novel proprietary technologies to specifically target cancer cells.
-
NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics to Develop Drug Candidates Including T Cell Suppressor Blockade
3/23/2020
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company announced it has entered into an exclusive license agreement with Ubix Therapeutics, Inc. to develop up to three drug candidates utilizing UBIX’s Degraducer® platform technology which enables target protein degradation.